¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º Y,r2m nq  
bBf+z7iyc  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ '_%Jw:4k  
JP]K\nQx'  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) rv[\2@}  
6lGL.m'Ra  
1. ICAM-1 Ra5cfkH;  
,$Mw/fA  
2. interleukin 12(IL-12) }% =P(%-  
w@4+&v>O  
3. tumor infiltrating lymphocyte oT'XcMn  
XN Y(@  
4. TCR/CD3 complex 0WFZx Ad"  
VQCPgs  
5. hematopoietin receptor family sC$X7h(Q+  
/>?d 2?  
6. individual idiotype(IdI) >3JOQ;:d8  
P%.5xYn  
7. integrin mnePm{  
>&TktQO_T  
8. colony-stimulatory factor (CSF) S'WmPv  
>2rFURcD  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 1_' ZbZv4h  
C'Ymz`iQ  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? {|fA{ Q_R  
q &+GpR  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ yP@= x!$  
*6h.#$\  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠw-KtxG(  
4bO 7rhve  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ DN!EsQ6  
@cx!m   
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 5rc<ibGh  
 ELm#  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ @/9> /?JP  
n4:WM+f4  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) rnW i<Se  
j8PK\j[  
3. immunoglobulin superfamily (IgSF) @a~K#Bvlm  
m\t %wr  
4. selectin m^ILcp!  
F8pLA@7[  
5. anti-idiotypic antibody (¦ÁId) ^PD a  
wk3yz6V2  
6. major histocompatibility complex(MHC) 9;@6iv  
`527vK 6  
7. immunotolerance L.8-nTg"y  
<EE)d@%>v  
8. biological reponse modifier(BRM) p1Els /|  
L:S[QwQu8  
9. immune reponse gene (Ir gene) mtHw! *  
{6n B83BB  
10. reshaped antibody (or reconstituted antibody) GI/g@RV  
!#>{..}}3  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 3 D\I#g  
?gTY! ;$P  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ Rh Yf+?2  
pN?  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? (pAGS{{  
]/U)<{6  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ _PJd1P.k  
HogT#BMs  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 3]V" 9+  
5*~G7/hT  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ edA.Va|0  
ZXp=QH+f  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? y_QK _R<f  
*;Sj&O  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ RHeql*`  
!}<Y^="  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ S)p1[&" M  
A=Dzd/CUO  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? LLCMp3qBz  
 Xji<oih  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ Q/L:0ovR  
?bW|~<X~  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: n-0RA~5z  
.r$d 8J  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: O6 bB CF;  
=UT*1-yh R  
ÃâÒßѧ CB:G4VqOT  
Z XlW_CGO  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© iW9G0Ay  
0"3l2Eo  
1. CD8 6O>NDTd%  
h`;w/+/Zr  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) fIWOo >)D  
7&-B6Y4  
3. immunoglobulin fold(Ig fold) My vp PW  
W^v3pH-y#  
4. cadherin (Ca-dependent cell adhesion moleculers) ezS@LFaA  
__O@w.  
5. idiotype-anti-idiotypic antibody immune network theory m:_'r"o  
^M_0M  
6. HLA class II antigen g ] %sX6T  
C3>&O?7J*7  
7. complementarity-determining region (CDR) lXso@TNrZ0  
XA PqRJ*Z  
8. perforin(or pore-forming protein ,PFP) EVYICR5g  
tX)l_ ?jVH  
9. high affinity IL-2 receptor l/ufu[x!a  
F`))qCgg]  
10. artificial active immunization QmxI ;l  
*ETSx{)8  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© *5T^wZpj)  
N=%4V  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ&puPn:_  
x6N)T4J(  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 EIdEXAC(  
xfegi$  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ ,r_%p<lOFu  
^W#161&  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ r8%"#<]/  
p#;I4d G  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ UmEc") 3  
j3=%J5<  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ) wqG^yv  
W! jg  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ <dd XvUCX  
X5_T?  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ tXXn HEz  
*TyLB&<t  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ^ jYE4gHM  
K&'Vd@  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ }z,f8Yz  
v{r,Wy3  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© OrP i ("/  
jCp^CNbA  
1. immunoglobulin gene rearrangement T;C0t9Yew  
8{4SaT.-Rm  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors)  -^ceTzW+  
;s\ck:Xg  
3. flow cytometry(FCM) 89Ch'D  
&zV; p  
4. carrier effect 5c ($~EFr  
v{8W+  
5. positive selection of T lymphocytes in thymus CaB@, L  
p>h&SD?b  
6. mouse TH1(Th1) and TH2(Th2) subsets M$Or|HTG  
IeT1Jwe  
7. perforin (pore-forming protein ,PFP) }cO}H2m  
68QA%m'J  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) W[B;;"ro  
#`qP7E w  
9. SH-2(src-homology region 2) v5A8"&Jr  
hZtJ LY  
10. Ab2¦Â (internal image) >Pwu>  
v=J[p;H^H  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 5pz( 6gA  
^oXLk&d  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? L(`Rf0smt  
N VBWF  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 4fL/,j/^  
r0:I  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ8m*uT< 5D  
\(;X3h  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ !g7bkA  
b |JM4jgK  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠBs;.oK5!n@  
|.{[%OJP  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) "PfNC<MQo  
f[+N=vr  
ÃâÒßѧרҵ£º (4"Azo*~![  
'D[g{LkL  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ |YWX.-aeo  
g3kF&+2i  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? &? z6f9*$  
ES9|e o6  
´«È¾²¡Ñ§×¨Òµ£º "2>_eZ#b  
%Kc2n9W  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ b$/ 'dnx  
X~> 2iL  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ %bZ}vJ5b  
U`)o$4Bq  
Ïû»¯×¨Òµ£º cRS2v--\-  
(C60HbL   
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ 65AG # O5R  
K [M[0D  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 5/C#*%EH'  
?)mM]2%%  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ nEbJ,#>Z  
p}9bZKyf  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© h?+bW'm  
'.1_anE]  
1. Fas(CD95)/FasL >'e(|P4  
|n q}#  
2. common chain of cytokine receptor -Gn0TA2/C  
,{VC(/d  
3 . TCR/CD3 complex ~|.vz!A  
=6 ^phZ(  
4. negaive selection of thymocytes \&. ]!!Q  
LS{t7P9K  
5. artificial active immune .7v .DR>  
=#K$b *#  
6. anti-idiotypic 3|9 U`@  
K6nGC  
7. IgSF Qz9*o  
&(t/4)IZox  
8. Integrin g}Esj"7  
"*N=aHsj  
9. chemokine 9e>Dqlv  
+ew9%={zB  
10. B7/CD28 |)W N%#v  
NvU~?WN  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© lx"#S '^~  
568qdD`PS  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ Q{"QpVY8  
dyN Kok#  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ k7\ ,N o}  
AHl1{* [  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ % 9lx)w  
]F81N(@:F  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ WjVj@oC  
:^[HDI-[2  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ Ccx1#^`  
b w2KD7  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ Fo@cz" %  
S#wy+*  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© W`2Xn?g  
vl67Xtk4  
1. B7/CD28 YN>k5\M_v  
a/v!W@Zz}  
2. Th1 subset QaYUcma~n  
jQIb :\0#  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© ,9@JBV%_  
<yq kJ  
4. antibody affinity maturation -xk. wWpV  
UB Z37P  
5. AP-1 2MQ XtK  
*eLKD_D`!C  
6. single chain variable fragment£¨ScFv£© k6b0& il  
`\vqDWh8-  
7. NK cell receptor >ukn<  
O7of9F~"  
8. Zinkernagel-Doherty phenomenon b2<((H  
_9<nM48+t  
9. Ig fold Q2(K+ !Oe  
!`h^S)$  
10. CD40/CD40L iS]4F_|vd  
9N@m><N84  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© g;n6hXq4  
suF<VJ)&s  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ _< LJQ  
E'ay @YAp  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ |@*3 nb8  
wS"`~Ql_  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 49?wEm#  
L%Mj{fJ>Wm  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 9(AY7]6  
mNk@WY_F  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ $3'xb/3|  
bCL/"OB  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ "pInb5 F  
Hq;*T3E  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ h7a/]~  
;Zt N9l  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© ?l>Ra0  
zc.r&(d  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Z(Z$>P&4  
%)#yMMhR  
1.Co-stimulators (or co-stimulating molecules) zb,YYE1  
m8Y>4:Nw  
2.NK-kB "~:P-]`G  
Z/e^G f#i  
3.Immunoglobulin superfamily me YS W  
O[j$n  
4.antigen-presenting cell (APC) 's\rQ-TV  
m}32ovpw  
5.death domain !IC@^kkh{  
7TB&Q*Zf  
6.CCR and CXCR W_bA .z T{  
cXIuGvE&=  
7.Lectin (or mitogen) pebNE 3`#  
v`\CzT  
8.Clusters of differentiation, CD) L~!Lq4]V\g  
:4x&B^,53  
9.B7 family [!j;jlh7},  
Z5` U+ (  
10.Cytotoxic T lymphocyte, CTL) p?' F$Wz  
q22@ZRw  
11.IL-15 and IL-15 receptor (IL-15R) h3(B7n7  
]T>|Y0|  
12.MHC restriction F#Bi*YY  
o@qI!?p&  
13.Affinity-chromatography F> b<t.yV  
J:dNV <A^  
14.Cyctosprin A, CsA (AT)w/  
RY9Ur  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) LDbo=w  
oR}'I  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© I@uin|X  
l<p6zD$l  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 r?R!/`f  
/ jN &VpDG  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ Dw&_6\F @  
Mo&Po9  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 0kL tL!3  
$`txU5#vs  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© k7=mxXF  
ktiC*|fd  
ÃâÒßѧרҵ£º o%l|16DR  
;mXw4_{  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 4fau 9bW  
JDm7iJxc_  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ +\~Mx>Cn  
f/]g@/`  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ J }s)#va9R  
#3((f[  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) Ks.kn7<l  
z=a{;1A  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) 84YZT+TEN  
-{a&Zkz>V  
1. ADCC(antibody dependent cell-mediated cytotoxicity) <rFKJ^B  
Pt8 U0)i)  
2. »·æß¾úËØ(cyclosporin) 5Y(f7,JX  
TkV*^j5  
3. KIR(killer cell inhibitory receptor) 16n8[U!  
NR Z>03w  
4. HLDA(human leucocyte differentiation antigen) y1+~IjY  
O;~d ao  
5. Interleukin 18(IL-18) mdPE F)-  
$.-\2;U  
6. ÕûºÏËØ(integrin) "+:~#&r  
m@^!?/as  
7. Fas/FasL k-a3oLCR,  
d}RR!i`<N  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 63n<4VSH  
I:G4i}mA  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) '{xPdN  
yZ]u{LJS  
10. Th1/Th2 dS m; e_s  
ESt@%7.F  
11. »ùÒòÒßÃç(DNAÒßÃç) Zjx:1c= b  
uRfFPOYH  
12. chemokines and chemokine receptor ,wE cRN w  
 d r iw\  
13. ÃâÒßÄÍÊÜ BNe6q[ )W~  
N9A#@c0O  
14. ¹²´Ì¼¤·Ö×Ó I@<\DltPi  
zwa%$U  
15. ËÀÍö½á¹¹Óò(death domain) >2w^dI2  
xLmgr72D  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) =1'vXPv`  
7; e$ sr  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? c$ skLz  
yMoV|U6  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠGnzKDDH '  
MQ{.%  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î |kXx9vGq@  
)IH|S5mG?  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ n$oHr  
?'$Yj>R6  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå BQ7p<{G  
fT.GYvt`  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ p2/Pj)2  
h vO  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 6S GV}dAx  
(:P-ef$]C  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ v?=y9lEH@%  
34gC[G=  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ V6ICR{y<3  
y`|86` Y  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»